For its second fiscal quarter (ending June 30), West Pharmaceutical Services Inc (NYSE: WST) has reported a -27% decline in E.P.S. from $2.08 a year ago to $1.52 in the current quarter. This performance was $-0.21 short of the consensus estimate of $1.73. For the latest four quarters through June 30, E.P.S. were $7.11 versus $6.96 for the same period a year ago — an increase of 2%.
Recent Price Action
On 7/25/24, West Pharmaceutical Services Inc (NYSE: WST) stock suffered a major decline of -14.4%, closing at $277.16. Moreover, exceptionally high trading volume at 532% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months and has declined -15.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, WST is expected to continue to be a major Value Builder.
West Pharmaceutical Services has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. West Pharmaceutical Services has a slightly negative Power Rating of 34 and a very low Appreciation Score of 11, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment